KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Halozyme Therapeutics (HALO) Long-Term Debt Issuances (2016 - 2022)

Halozyme Therapeutics (HALO) has disclosed Long-Term Debt Issuances for 3 consecutive years, with $120.0 million as the latest value for Q2 2022.

  • On a quarterly basis, Long-Term Debt Issuances rose 480100.0% to $120.0 million in Q2 2022 year-over-year; TTM through Dec 2023 was $120.0 million, a 118.05% increase, with the full-year FY2025 number at $735.0 million, changed N/A from a year prior.
  • Long-Term Debt Issuances was $120.0 million for Q2 2022 at Halozyme Therapeutics, up from -$784.9 million in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $784.9 million in Q1 2021 to a low of -$784.9 million in Q4 2021.